Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY vs ARALEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Treatment of uncomplicated malaria caused by susceptible strains of Plasmodium vivax, P. malariae, P. ovale, and P. falciparum,Prophylaxis of malaria in areas with chloroquine-sensitive P. falciparum,Treatment of extraintestinal amebiasis (as amebicide) and giardiasis (off-label),Disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis and lupus erythematosus (off-label)
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Terminal elimination half-life ranges from 30 to 60 days (mean ~45 days) due to extensive tissue binding; clinical context: prolonged half-life allows weekly dosing for malaria prophylaxis.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Chloroquine is extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2C8 and CYP3A4, to active metabolites such as desethylchloroquine. It has a long elimination half-life of approximately 1-2 months.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
Primarily renal (approximately 70% as unchanged drug); minor biliary/fecal (about 10-20%).
>99% bound to albumin and alpha-1-acid glycoprotein.
Approximately 50-60% bound; primarily to albumin and alpha-1-acid glycoprotein.
4.9 L/kg (high distribution into tissues).
Very large, 100-200 L/kg; extensive tissue distribution (liver, spleen, kidney, lungs, melanin-containing tissues).
Oral: 87% (tablet and solution); IM: 100%.
Oral: 80-90%.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
For malaria prophylaxis: No adjustment necessary. For treatment: If Cr Cl < 10 m L/min, reduce dose by 50%.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
No formal guidelines; use caution in severe hepatic impairment due to potential accumulation. Consider dose reduction in Child-Pugh class C.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Prophylaxis: 5 mg/kg base (8.3 mg/kg salt) orally once weekly, max 300 mg base. Treatment: 10 mg/kg base (16.7 mg/kg salt) orally initially, followed by 5 mg/kg base at 6, 24, and 48 hours, max 600 mg base on day 1.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
No specific adjustments; consider age-related renal impairment and potential increased risk of QT prolongation. Monitor for cardiac effects.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
Retinopathy: Irreversible retinal damage including retinopathy and visual disturbances; risk increases with cumulative dose and duration of use; contraindicated in patients with pre-existing retinopathy; baseline and periodic ophthalmologic exams required.
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Retinopathy risk with prolonged use; cardiac effects including conduction disorders (e.g., QT prolongation) and cardiomyopathy; exacerbation of psoriasis and porphyria; neuropsychiatric effects (e.g., psychosis, seizures); hematologic toxicity (eg, agranulocytosis, aplastic anemia); hypoglycemia; myopathy; ototoxicity. Use with caution in hepatic or renal impairment, G6PD deficiency, and pregnancy (benefit vs risk).
Known hypersensitivity to aripiprazole or any of its excipients.
Hypersensitivity to chloroquine or 4-aminoquinolines; pre-existing retinopathy of any etiology; concurrent use with other agents causing retinal toxicity (e.g., hydroxychloroquine, tamoxifen); porphyria; psoriasis (relative, may exacerbate); neuromyopathy (relative); severe hepatic or renal impairment (relative).
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
Avoid grapefruit juice as it may increase chloroquine levels. No other significant food interactions.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third trimesters: Risk of sensorineural hearing loss, vestibular damage, and retinal toxicity in the fetus if used for prolonged periods or at high doses; accumulation in fetal ocular tissues reported.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
Excreted in breast milk in small amounts (M/P ratio approximately 0.44). American Academy of Pediatrics considers compatible with breastfeeding, but caution is advised in infants with glucose-6-phosphate dehydrogenase deficiency or hemolytic disease. Monitor infant for rash, retinal changes, and hemolysis.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
No specific dose adjustment recommended for pregnancy; pharmacokinetic changes (increased volume of distribution, decreased plasma concentrations) may require therapeutic drug monitoring, but empirical dose adjustments are not established. Use lowest effective dose and shortest duration.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
Chloroquine (Aralen) can cause retinal toxicity; cumulative dose should not exceed 200g. Use with caution in G6PD deficiency. Can prolong QTc interval; avoid with other QTc-prolonging drugs.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
Take with food to reduce gastrointestinal upset.,Do not exceed prescribed dose; overdose can be fatal.,Report any vision changes immediately; regular eye exams are required.,Avoid alcohol as it may increase risk of liver toxicity.,Inform your doctor if you have a history of heart rhythm problems.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY vs ARALEN, answered by our medical review team.
ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. ARALEN is a Antimalarial that works by Chloroquine, a 4-aminoquinoline, accumulates in acidic organelles such as food vacuoles of malaria parasites, inhibiting heme polymerase and preventing the conversion of toxic heme to hemozoin. It also interferes with DNA synthesis and repair by intercalating into DNA. Additionally, it has immunomodulatory effects via inhibition of Toll-like receptors and cytokine production.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY and ARALEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. The standard adult dose of ARALEN is: Adults: 500 mg (300 mg base) orally once weekly on the same day each week for prophylaxis of malaria; 1 g (600 mg base) orally initially, followed by 500 mg (300 mg base) at 6, 24, and 48 hours for treatment of acute malaria.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY and ARALEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. ARALEN is classified as Category C. Pregnancy category C. First trimester: No conclusive evidence of major malformations in human studies, but animal studies show embryotoxicity and fetotoxicity. Second and third tri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.